Publication | Closed Access

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

ThrombosisCardiovascular DiseaseBlood PlateletMedicineSecondary PreventionPharmacologyClinical TrialsCardiovascular PharmacologyHigh-risk Primary PreventionPharmacotherapyIschemic StabilizationPlatelet AntagonistStrokeAnticoagulantAtherosclerosis